Tvardi Therapeutics opened lower at $1.30, compared with its previous close of $1.34. In the last trading session, the stock traded between $1.15 and $1.30. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Tvardi Therapeutics is now worth
$ 6.31
Resulting in a loss of
$ 93.69 (93.69%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
0%
Sell
16.67%
Markets Today
Today's Change
$-0.19 (-14.10%)
Day High
$1.30
Day Low
$1.15
Day Open
$1.30
Prev Close
$1.34
Volume
1,55,355
1W Return
33.99%
1M Return
9.10%
3M Return
-34.79%
6M Return
-70.93%
1Y Return
-72.53%
Fundamentals
Market Cap ($ Mn)
15
PE Ratio
-
PB Ratio
2.04
PEG Ratio
-
ROE
-
ROCE
-67.71%
EPS (TTM)
-
Investment Returns
1 Week
33.99%
1 Month
9.10%
3 Months
-34.79%
6 Months
-70.93%
9 Months
-69.55%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
2.6
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
24Sep
Tvardi STAT3 inhibitor shows 8-fold colon exposure in UC models
TTI-101 achieved approximately 8-fold higher drug concentrations in the colon than in plasma. Preclinical model showed complete prevention of adenocarcinoma formation with p≤0.05 significance. Colon drug levels exceeded STAT3 IC50 by more than 20 times. TTI-109 Phase 1 study showed favorable GI tolerability and immune cell modulation.
1mo ago
14Aug
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31%
Tvardi Therapeutics reported Q2 EPS of $(0.69), beating estimates of $(0.70) and narrowing losses 31% YoY. Net loss was $6.5M vs $4.2M profit in Q2 2025, driven by absence of non-cash gains. Operating expenses fell to $6.6M from $8.9M. Cash runway extends to Q3 2027.
3mo ago
30Jul
Tvardi Therapeutics targets ulcerative colitis with TTI-109
Tvardi Therapeutics selects ulcerative colitis as the initial indication for TTI-109, driven by Phase 1 data showing up to 76% reduction in Th17 immune subsets. The company targets a $9 billion global market with an oral STAT3 inhibitor, planning trials in 2027 pending IND clearance and funding.
3mo ago
18Jul
Tvardi Therapeutics increases ATM offering to $9.69M
Tvardi Therapeutics increased its At-The-Market offering program to $9.69M in shares, according to an SEC filing. The company filed the update to reflect the new aggregate offering amount under the program.
3mo ago
9Jul
Tvardi stock falls as investors book gains after Phase 1 data
Tvardi Therapeutics Inc. reported positive Phase 1 data for TTI-109, showing rapid conversion to TTI-101 and reduced immune cell populations, leading to a prior stock surge. The stock subsequently fell in premarket trading as investors took profits, with technical analysis indicating overbought conditions.
4mo ago
8Jul
Raymond James upgrades Tvardi Therapeutics to Outperform
Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics to Outperform from Market Perform with a $10 price target. BTIG analyst Julian Harrison reaffirmed a Buy rating with a $15 target.
